Glycolysis: Steps, Products & Enzyme Deficiencies
Glycolysis shows up on Step 1 more than students expect. It is not just a list of ten enzymes to memorize and forget. The exam uses it as an anchor for regulation, enzyme deficiency recognition, and clinical reasoning about energy metabolism. Every year, questions about lactic acidosis, hemolytic anemia, and cancer metabolism trace back to concepts that live entirely inside this pathway.
What follows is the glycolysis information that actually moves scores: the glycolysis steps that are tested by name, the net-yield math, the PFK-1 regulatory axis, and the enzyme deficiencies the test reaches for repeatedly. Students who are performing well can use this to build a working map they can reason from. Students who are struggling can use it to stabilize the highest-yield pieces first, then fill in the rest.
What Glycolysis Does (and Where It Does It)
Glycolysis converts one molecule of glucose into two molecules of pyruvate. Every step occurs in the cytosol. No mitochondria are required, which is exactly why red blood cells (which lack mitochondria entirely) depend on it as their sole ATP source.
The pathway splits into two phases. Steps 1 through 5 make up the investment phase: the cell spends 2 ATP to phosphorylate and cleave glucose. Steps 6 through 10 make up the payoff phase: the cell generates 4 ATP and 2 NADH from two molecules of glyceraldehyde-3-phosphate. The net result is 2 ATP, 2 NADH, and 2 pyruvate per glucose.
That number, 2 ATP net, is what Step 1 means when it asks about the ATP yield of glycolysis. Not 36, not 38, not 32. Those larger numbers include oxidative phosphorylation. Glycolysis alone yields 2.
Net Yield: The Numbers Step 1 Asks About
Students spend too much time trying to memorize whether the total aerobic yield is 30, 32, 36, or 38 ATP. The glycolysis products that actually appear on Step 1 questions are the net figures: 2 ATP, 2 NADH, and 2 pyruvate per glucose. The total aerobic yield varies by source and by which NADH shuttle assumption you use. What does not vary, and what appears on board questions without ambiguity, is the net yield of glycolysis itself.
⚠ Common Mistake
Confusing the net ATP yield of glycolysis (2) with the total aerobic yield of glucose oxidation (~30–32). If a question specifies “glycolysis only” or asks about an anaerobic cell, the answer is 2 ATP. Picking a larger number here is a reliable indicator that the concept has not yet been sorted out.
The Three Irreversible Enzymes
These three enzymes catalyze reactions that are thermodynamically irreversible under physiologic conditions. They are the primary regulatory points of glycolysis, and they are the exact steps gluconeogenesis must bypass with different enzymes. If only one thing gets memorized from this section, it should be this table.
| Enzyme | Step | Tissue | Key Regulation | Gluconeogenesis Bypass |
|---|---|---|---|---|
| Hexokinase / Glucokinase | Step 1 | Hexokinase: most tissues. Glucokinase: liver and β-cells only. | Hexokinase inhibited by G6P. Glucokinase: high Km, not product-inhibited, induced by insulin. | Glucose-6-phosphatase |
| Phosphofructokinase-1 (PFK-1) | Step 3 | All tissues | Rate-limiting. Activated by AMP, F-2,6-BP. Inhibited by ATP, citrate. | Fructose-1,6-bisphosphatase |
| Pyruvate Kinase | Step 10 | All tissues (PKLR isoform in RBCs and liver) | Activated by F-1,6-BP (feed-forward). Inhibited by ATP, alanine. Glucagon suppresses via phosphorylation. | Pyruvate carboxylase + PEPCK |
PFK-1: The Glycolysis Rate-Limiting Enzyme
PFK-1 is the glycolysis rate-limiting enzyme, the committed step that determines whether a cell is running glycolysis at full speed or holding back. Committed means that once fructose-6-phosphate is converted to fructose-1,6-bisphosphate, the cell is committed to completing the pathway. Regulation here reflects the cell’s energy state.
The logic is worth internalizing rather than memorizing in isolation. When AMP is high, the cell is depleted of energy, and PFK-1 accelerates. When ATP and citrate are high, the cell has plenty of fuel, and PFK-1 slows. Fructose-2,6-bisphosphate (F-2,6-BP), produced by the bifunctional enzyme PFK-2/FBPase-2, is the most potent activator of PFK-1 and the central target of insulin and glucagon signaling.
Hexokinase has a low Km (high affinity for glucose) and is inhibited by its product, glucose-6-phosphate; it operates near saturation at normal blood glucose levels. Glucokinase has a high Km (low affinity) and is not product-inhibited. This makes glucokinase a glucose sensor: activity increases proportionally as postprandial glucose rises, allowing the liver to buffer the glucose load. Glucokinase mutations cause MODY type 2.
Aerobic vs. Anaerobic Glycolysis
Glycolysis itself is the same ten steps regardless of oxygen availability. The divergence occurs after pyruvate is produced at step 10. When oxygen is available, pyruvate is converted to acetyl-CoA and enters the Krebs cycle.
Two Concepts Worth Knowing Cold
The Pasteur Effect: Oxygen suppresses the rate of glycolysis. Aerobic conditions raise ATP and citrate, which inhibit PFK-1. Glucose consumption slows because the cell no longer needs to burn it at high speed to maintain ATP. Hypoxia accelerates glycolysis by the same logic in reverse.
The Warburg Effect: Cancer cells preferentially perform aerobic glycolysis, producing lactate even when oxygen is present. This is the basis of ¹⁸F-FDG PET imaging. Tumors consume glucose at high rates and appear as bright spots on PET. Step 1 questions about cancer metabolism or PET scans connect back here.
High-Yield: Glycolysis-Dependent Tissues
Mature RBCs (no mitochondria), cornea, lens, renal medulla, and testes rely heavily or exclusively on anaerobic glycolysis for ATP. RBCs are the highest-yield of these. The reason pyruvate kinase deficiency causes hemolytic anemia (and not a myopathy) is that RBCs have no backup pathway.
Enzyme Deficiencies Step 1 Tests
Three deficiencies come up repeatedly. Each has a distinct clinical signature. The trap with Von Gierke is that it looks like a glycolysis defect but is actually a block in gluconeogenesis and glycogenolysis. The trap with pyruvate kinase deficiency is that students expect spherocytes and do not find them.
How to Study This Based on Where You Are
- Master the PFK-2/FBPase-2 bifunctional enzyme axis. Know the insulin vs. glucagon effect at the molecular level: which PKA phosphorylation event activates, and what happens to F-2,6-BP.
- Connect glycolysis to the TCA cycle via PDH and to gluconeogenesis via the bypass enzymes. Questions that test both pathways in one vignette require that map.
- Know why 2,3-BPG rises in PK deficiency, why that right-shifts the O₂-Hb curve, and why the anemia is better tolerated than the hemoglobin level suggests.
- Practice Warburg-effect and lactic acidosis questions. The clinical application is where high-scorers separate.
- Anchor to the three irreversible enzymes and their clinical consequences first. Steps 2, 4, 5, 8, and 9 are almost never the answer on Step 1.
- Memorize the net yield cold: 2 ATP, 2 NADH, 2 pyruvate. No exceptions for the glycolysis number.
- Learn one discriminating fact per deficiency: echinocytes/no spherocytes for PK deficiency; high Km/MODY for glucokinase; lactic acidosis plus fasting hypoglycemia for Von Gierke.
- Do not memorize all 10 steps in detail before owning the regulation and deficiency material. The payoff phase is secondary to the regulatory logic.
What Wastes Time on This Topic
Common Time Wasters
Drawing the full pathway repeatedly without testing yourself on it. Memorizing the exact ATP counts for aerobic respiration across all sources (the numbers genuinely vary by textbook; know “~30–32” and move on). Over-reading enzyme kinetics for steps 2, 4, 5, 8, and 9, none of which are regulatory or have associated deficiency syndromes. Getting lost in the Warburg effect mechanistic literature instead of knowing the exam point: cancer cells preferentially use glycolysis even with O₂, which is the basis of PET imaging.
Practice Questions
Work through these before reviewing the explanations. The stem logic reflects how Step 1 actually constructs glycolysis questions.
A 4-month-old male is brought for evaluation of jaundice and pallor. Labs show hemoglobin 7.8 g/dL, elevated indirect bilirubin, and elevated LDH. Peripheral smear shows irregularly spiculated red cells with no spherocytes. Osmotic fragility testing is normal. Upstream glycolytic intermediates are elevated. Which enzyme deficiency is most consistent with this presentation?
Pyruvate kinase deficiency. The key discriminators are: (1) echinocytes (burr cells), not spherocytes, which suggest hereditary spherocytosis or immune hemolysis; (2) normal osmotic fragility, ruling out hereditary spherocytosis; (3) elevated upstream intermediates, because the block is at pyruvate kinase (step 10), so everything upstream accumulates, including 2,3-BPG, which rises to compensate by right-shifting the O₂-Hb curve. The autosomal recessive PKLR mutation causes the PKLR isoform to malfunction specifically in RBCs and liver.
A 6-month-old presents with severe fasting hypoglycemia, hepatomegaly, and elevated serum lactate. Glucose-6-phosphatase activity is absent on liver biopsy. Which of the following best explains the lactic acidosis in this patient?
Excess glycolysis from accumulated glucose-6-phosphate. Without glucose-6-phosphatase, G6P cannot be converted to free glucose and exits via glycolysis instead, producing excess pyruvate and lactate. This is not Type A lactic acidosis from hypoxia; it is a metabolic consequence of pathway redirection. The high-yield lesson: lactic acidosis in Von Gierke is a glycolysis overflow, not an oxygen-delivery problem. Recognize the constellation: fasting hypoglycemia, lactic acidosis, hepatomegaly, and hyperuricemia.
A 28-year-old woman is found to have fasting glucose of 118 mg/dL on a routine screening panel. She has no symptoms. Her mother had a similar finding for years without progression to diabetes or complications. Genetic testing reveals a heterozygous GCK mutation. What is the mechanism of her hyperglycemia?
Glucokinase deficiency (MODY type 2). Glucokinase acts as the glucose sensor in pancreatic β-cells. Its high Km means activity is proportional to glucose concentration over the physiologic range. With reduced glucokinase function, the threshold for insulin secretion rises; the β-cell requires a higher blood glucose level before releasing insulin. The result is mild, stable fasting hyperglycemia that rarely progresses. This is not Type 1 or Type 2 diabetes; it is a glucokinase (hexokinase IV) deficiency. Autosomal dominant inheritance means one functional allele is lost.
Free USMLE Step 1 Practice Questions
Ready to Test What You Know?
Reading the pathway is the easy part. Try our free USMLE Step 1 practice questions, written as clinical vignettes in the same format as the real exam, and see which biochemistry concepts actually stick before exam day.
Try Free Questions →